CRP and lung cancer: Recently, a large randomized double-blind trial involving 10,061 patients with previous myocardial infarction and a CRP level of ≥2 mg/L suggested anti-inflammatory therapy with canakinumab, a monoclonal antibody targeting interleukin-1, may be effective in reducing the incidence and mortality of lung cancer in addition to reducing non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death (12, 13).